CERATIUM BV

Their core work

CERATIUM BV is a Dutch biotech SME that operates at the intersection of translational life sciences — contributing to both agricultural biotechnology and therapeutic development. In plant science, they bring expertise in photosynthesis optimization, germplasm phenotyping, and bridging fundamental plant biochemistry to real-world crop improvement. On the medical side, they are involved in the clinical development of mRNA-based cancer vaccines targeting HPV-driven tumors, working at the proof-of-principle and early Phase 1/2a stage. The breadth of their portfolio across two very different biotech domains suggests they function as a specialist contributor with transferable expertise in translational science methodology rather than a single-domain operator.

What they specialise in

How they've shifted over time

CERATIUM's two H2020 projects reveal a sharp pivot across a short window. Their first project (CAPITALISE, starting 2020) is firmly rooted in agricultural biotechnology — photosynthesis, plant breeding, germplasm, and environmental physiology. By 2021, their second project (TIGER) shifts entirely into oncology — mRNA vaccines, HPV cancer immunotherapy, and clinical trial preparation, with no overlap in terminology. Whether this reflects a deliberate strategic pivot from agri-biotech to medtech, or represents a genuinely multi-domain consultancy offering specialist input to diverse consortia, cannot be determined from this data alone.

CERATIUM appears to be moving toward therapeutic biotech — specifically mRNA immunotherapy for cancer — which aligns with one of the fastest-growing areas of European life science investment post-2020.

How they like to work

CERATIUM has participated exclusively as a consortium partner across both projects and has never led an H2020 project as coordinator. They integrate into large, multi-partner research consortia (27 unique partners across just 2 projects), suggesting they are sought as a specialist contributor rather than a project driver. This profile is typical of SMEs that offer a niche capability or service that larger academic or industry partners need but do not hold in-house.

Despite only two projects, CERATIUM has built connections with 27 unique consortium partners across 10 countries — an unusually broad network for a two-project participant. This suggests they joined large, geographically diverse consortia, which is consistent with both CAPITALISE (European-scale agri-science) and TIGER (multi-country clinical trial infrastructure).

What sets them apart

CERATIUM is a rare SME that has contributed to both plant-based and human therapeutic biotech within H2020, spanning agri-food and oncology — two sectors that rarely share partners. For consortium builders, this cross-domain life science profile means CERATIUM can bring translational methodology, biotech process know-how, or sector-bridging insight that single-domain organizations cannot offer. Their Amsterdam base and SME status also make them attractive for consortia seeking Dutch private sector participation with a translational biotech angle.

Highlights from their portfolio

• CAPITALISE
  The largest of CERATIUM's two projects (€529,910), focused on improving photosynthetic efficiency across European crops — a high-priority challenge for agricultural sustainability and food security.
• TIGER
  A proof-of-principle clinical trial for a TriMix mRNA cancer vaccine targeting HPV-associated tumors, placing CERATIUM at the early clinical frontier of cancer immunotherapy at a time when mRNA platforms were gaining rapid regulatory momentum.